[Special Stock] Celltrion Trio Rises on News of COVID-19 Test Kit Supply to US

[Asia Economy Reporter Ji Yeon-jin] Celltrion and its affiliates are showing strong performance following news that the company will supply COVID-19 antigen rapid test kits to the U.S. Department of Defense.

As of 10:06 AM today, Celltrion's stock price rose 2.90% (8,000 KRW) from the previous day to 283,500 KRW. At the same time, Celltrion Pharm, listed on the KOSDAQ market, jumped 4.69%, and Celltrion Healthcare also recorded a 2.04% increase.

Earlier, Celltrion announced that it will supply the COVID-19 antigen rapid test kit 'DiaTrust (Celltrion DiaTrustTM COVID-19 Ag Rapid Test)', jointly developed with in vitro diagnostics specialist Humasis, within the U.S. through its American subsidiary CelltrionUSA.

According to Celltrion, its U.S. subsidiary CelltrionUSA was finally selected as a supplier in a procurement project conducted by the Defense Logistics Agency (DLA) under the U.S. Department of Defense. Starting as early as next month on the 1st, weekly supplies of the DiaTrust antigen rapid test kits will begin to 25,000 designated procurement locations across the U.S., including military facilities, nursing homes, regional testing centers, and major facilities.

The contract period extends until September 16 of next year, with the contract amount potentially increasing up to 738.2 billion KRW depending on circumstances. This is the largest scale among the suppliers selected this time. The company explained that it is very rare for a Korean company to secure the largest contract in a large-scale procurement project by the U.S. Department of Defense, which involved multiple global companies.

This content was produced with the assistance of AI translation services.